Clinical operations teams have been burned by patient research vendors before. The pattern is familiar: a study scoped in a discovery call, a statement of work that looks reasonable, and then the slow unraveling — recruitability problems that nobody flagged, timelines that slip without warning, sample quality that doesn’t hold up under scrutiny. By the time the problems surface, the development timeline has absorbed the damage.
The failure usually doesn’t start at execution. It starts at commitment — specifically, at the moment a vendor agrees to a study without having genuinely assessed whether it’s deliverable.
The gap between "yes" and "can we actually do this"
Most patient research vendors operate on an optimistic assumption: that the target population is reachable, that the inclusion and exclusion criteria map to real-world patients, that the timeline is achievable. Those assumptions get tested later, usually at the worst possible moment.
The questions that should be answered before any study begins are specific and unglamorous: Can we recruit against these I/E criteria from a verified patient population within this timeline? Does the regulatory complexity fit the scope? Do we have the analyst capacity to hit milestones without compromising delivery?
Answering those questions honestly — before a SOW is signed — is what separates a study that delivers from one that becomes a vendor management problem.
Inspire evaluates every study against these criteria before committing. If the population isn’t reachable at the required scale within the timeline, that conversation happens at the front end, not six weeks in. If the regulatory burden doesn’t fit the scope, the study gets restructured or declined. That internal discipline is what makes delivery commitments credible — not optimism about what might be possible.
What patients will tell you that your protocol won't
Protocol design failures tend to cluster around the same problems: eligibility criteria that sound reasonable on paper but exclude most real-world patients, visit schedules that work in theory but create impossible burdens in practice, and comparator arms that patients find unacceptable — leading to enrollment refusals that never show up in planning assumptions.
Each of these is detectable before lock, with the right patient input.
In a study with a client developing a trial for scleroderma-associated interstitial lung disease (SSc-ILD), Inspire fielded quantitative surveys and virtual patient interviews in 14 days — with translations, moderation, and native transcripts included. The output was a set of specific recommendations on how to define clinical endpoints, structure eligibility criteria, and design a recruitment strategy around patient preference rather than operational convenience. Those recommendations didn’t extend the timeline. They protected it.
AI can optimize your protocol. It can't tell you if patients will tolerate it.
Predictive modeling and AI-assisted protocol design have become standard tools in clinical operations. Sponsors are using them to model enrollment scenarios, forecast screen failure rates, and stress-test timelines before a site is activated.
What those models can’t do is tell you how a patient with moderate-to-severe fatigue actually feels about a six-hour site visit. Or whether the inclusion criteria that look clean in a claims dataset exclude the majority of patients who are actively seeking treatment. Or whether a twice-weekly dosing schedule is something real people can sustain alongside jobs, caregiving responsibilities, and the baseline burden of managing a chronic illness.
AI works on the data it has. The data it doesn’t have is patient-reported experience — and that gap is where protocols get into trouble.
In a study conducted through Inspire’s digital community, 200 patients taking GLP-1 therapies were recruited in eight business days for a fully self-directed research protocol that included daily symptom diaries and an at-home blood draw using a novel collection device. Seventy-five percent completed every assigned task. The finding wasn’t just about recruitment speed — it was evidence that patient willingness and patient capability, when measured directly rather than modeled, produce design assumptions you can actually build on.
The question worth asking before you finalize the design
When clinical operations teams skip patient input at the protocol design stage, the implicit assumption is that the design is already right — or that fixing it later will cost less than validating it now. Given what protocol amendments, screen failures, and retention problems actually cost, that calculation rarely holds up.
The more useful question isn’t whether to collect patient input before you finalize a protocol. It’s whether you’re working with a research partner who has genuinely assessed whether the study is deliverable — and who will tell you honestly if it isn’t.
Inspire works with clinical development and operations teams across therapeutic areas to pressure-test protocol assumptions before they become protocol problems. If you’re approaching a design lock and haven’t asked your patients whether the study works for them, that’s the question worth starting with.